Teladoc Health Inc (NYSE:TDOC) – Equities research analysts at SunTrust Banks lifted their FY2019 earnings per share (EPS) estimates for shares of Teladoc Health in a research note issued to investors on Monday, December 2nd, Zacks Investment Research reports. SunTrust Banks analyst S. Draper now expects that the health services provider will earn ($1.56) per share for the year, up from their previous forecast of ($1.57). SunTrust Banks currently has a “Hold” rating and a $80.00 target price on the stock. SunTrust Banks also issued estimates for Teladoc Health’s Q4 2019 earnings at ($0.34) EPS and FY2021 earnings at ($1.23) EPS.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. The business had revenue of $137.96 million during the quarter, compared to the consensus estimate of $136.46 million. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The business’s revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) earnings per share.
Several other research analysts have also recently issued reports on TDOC. Jefferies Financial Group cut shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $80.00 price objective for the company. in a report on Friday, December 6th. Stifel Nicolaus assumed coverage on Teladoc Health in a research report on Monday, November 25th. They issued a “hold” rating and a $83.00 target price for the company. KeyCorp increased their price target on Teladoc Health from $75.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. ValuEngine downgraded Teladoc Health from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, Zacks Investment Research lowered Teladoc Health from a “buy” rating to a “hold” rating and set a $89.00 price objective for the company. in a report on Wednesday, November 27th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $81.00.
TDOC traded up $0.83 on Wednesday, reaching $83.35. The company had a trading volume of 557,190 shares, compared to its average volume of 1,322,939. Teladoc Health has a one year low of $46.00 and a one year high of $86.30. The company has a market capitalization of $5.99 billion, a P/E ratio of -57.88 and a beta of 1.40. The company has a fifty day moving average of $80.49 and a 200-day moving average of $69.65. The company has a current ratio of 6.55, a quick ratio of 6.55 and a debt-to-equity ratio of 0.44.
A number of hedge funds and other institutional investors have recently bought and sold shares of TDOC. Jennison Associates LLC lifted its holdings in shares of Teladoc Health by 60.6% in the second quarter. Jennison Associates LLC now owns 1,172,135 shares of the health services provider’s stock valued at $77,841,000 after purchasing an additional 442,140 shares in the last quarter. Aperio Group LLC lifted its stake in Teladoc Health by 28.3% in the 2nd quarter. Aperio Group LLC now owns 7,170 shares of the health services provider’s stock worth $476,000 after acquiring an additional 1,582 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Teladoc Health by 5.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 583,858 shares of the health services provider’s stock worth $38,775,000 after acquiring an additional 32,535 shares in the last quarter. Torray LLC purchased a new stake in Teladoc Health in the 3rd quarter worth about $930,000. Finally, C WorldWide Group Holding A S boosted its position in Teladoc Health by 124.0% during the 2nd quarter. C WorldWide Group Holding A S now owns 234,834 shares of the health services provider’s stock worth $15,595,000 after acquiring an additional 130,000 shares during the period.
In other Teladoc Health news, insider Adam C. Vandervoort sold 50,955 shares of the company’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $75.00, for a total transaction of $3,821,625.00. Following the completion of the sale, the insider now directly owns 9,769 shares of the company’s stock, valued at $732,675. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Lewis Levy sold 675 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $70.00, for a total transaction of $47,250.00. Following the completion of the transaction, the insider now owns 4,805 shares of the company’s stock, valued at $336,350. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,099 shares of company stock valued at $5,119,977. Corporate insiders own 3.95% of the company’s stock.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
